Risk is inherent to cannabis operations, regardless of cannabinoid profile.  That risk extends to retail end users that are consuming products that aren’t extensively researched, from processes that aren’t sufficiently regulated.  Delta-8 THC (∆8THC) is a prime example, but one that many readers will distance themselves from.  It has had far more impact on cannabinoid markets than CBD or CBG in the last year. 

Shipping extracts with any amount of ∆9THC has been the primary risk to hemp operators to date, and previous Hemp Bulletin commentary has illustrated that risk through stories like the unfortunate episode with